NCT03316794 - A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions

Breast Cancer

Interventions

DRUG

SC-005

intravenous

Trial Locations (8)

Memorial Sloan Kettering /ID# 201016, New York

Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233, Nashville

Gabrail Cancer Center Research /ID# 168756, Canton

Washington University School /ID# 169177, St Louis

Oklahoma University /ID# 200937, Oklahoma City

Baylor University /ID# 169860, Houston

MD Anderson Cancer Center /ID# 169232, Houston

University of Chicago /ID# 169231, Chicago